About
deCODE genetics is a pioneering human genetics research organization founded in 1996 and based in Reykjavik, Iceland. As a wholly owned subsidiary of Amgen, deCODE operates the most productive human gene discovery engine in the world, combining unrivaled population genetics databases with advanced computational analysis and AI-driven bioinformatics pipelines. The company's core mission is to decode the human genome to understand the genetic basis of common diseases. By leveraging Iceland's uniquely homogeneous and well-documented population, deCODE has identified key genetic risk factors for dozens of conditions including cardiovascular disease, cancer, Alzheimer's disease, diabetes, and autoimmune disorders such as lupus. These findings are validated through large-scale genome-wide association studies (GWAS) and whole-genome sequencing. deCODE's discoveries are routinely published in leading peer-reviewed journals such as Nature Genetics, providing the global scientific community with foundational insights for further research and therapeutic development. The organization also translates its genetic findings into drug targets and biomarkers that inform Amgen's pharmaceutical pipeline. Primary users include pharmaceutical researchers, academic geneticists, biotech companies, and clinical scientists seeking to understand disease mechanisms and identify novel therapeutic targets. deCODE represents a unique intersection of population-scale data science, computational genomics, and real-world medical research.
Key Features
- World-class Gene Discovery Engine: Operates the most productive human gene discovery platform globally, identifying genetic variants associated with major diseases through large-scale GWAS and whole-genome sequencing.
- Unique Icelandic Population Database: Leverages Iceland's genetically homogeneous and well-documented population, providing unrivaled statistical power for identifying rare and common genetic variants.
- Disease Genetic Risk Factor Identification: Has discovered key genetic risk factors for dozens of diseases including cardiovascular disease, cancer, diabetes, Alzheimer's, and autoimmune conditions like lupus.
- Peer-reviewed Scientific Publications: Regularly publishes breakthrough findings in top-tier journals such as Nature Genetics, enabling global validation and expansion of genetic discoveries.
- Drug Target & Biomarker Translation: Translates genetic discoveries into actionable drug targets and biomarkers that feed into Amgen's pharmaceutical R&D pipeline.
Use Cases
- Identifying genetic risk variants for cardiovascular disease to guide preventative medicine and drug development
- Discovering rare gene mutations linked to autoimmune disorders such as lupus for targeted therapeutic research
- Providing Amgen's R&D pipeline with validated genetic drug targets derived from population-scale genomic studies
- Supporting academic collaborators with large-scale GWAS data and genome-wide sequencing resources
- Publishing foundational genomics research that enables global scientific communities to build new disease models and therapies
Pros
- Unmatched Population Genetics Resources: Iceland's unique population offers exceptional data quality and statistical power for genetic studies, giving deCODE a distinct scientific advantage over competitors.
- Proven Track Record of Discovery: Decades of published, peer-reviewed research across dozens of disease areas demonstrate deCODE's ability to produce reproducible and globally impactful findings.
- Amgen Backing for Scale: As an Amgen subsidiary, deCODE benefits from substantial resources and a direct pipeline from genetic discovery to drug development and commercialization.
Cons
- Not a Consumer-facing Tool: deCODE genetics is a research organization, not a self-service platform — access to data and services is not available to general users or small teams.
- Geographic and Population Specificity: The primary dataset is based on the Icelandic population, which may limit direct generalizability of findings to other ethnic groups without additional validation studies.
- Limited Public Tooling or API Access: deCODE does not publicly offer APIs, datasets, or SaaS tools; engagement is primarily through academic collaboration or Amgen partnership channels.
Frequently Asked Questions
What is deCODE genetics?
deCODE genetics is a human genetics research company founded in 1996, headquartered in Reykjavik, Iceland, and wholly owned by Amgen. It specializes in identifying genetic risk factors for common diseases using large-scale genomic analysis of Iceland's population.
What diseases has deCODE studied?
deCODE has discovered genetic risk factors for dozens of conditions including cardiovascular disease, various cancers, Alzheimer's disease, diabetes, schizophrenia, and autoimmune diseases such as systemic lupus erythematosus (SLE).
How does deCODE use AI and computational methods?
deCODE employs advanced computational genomics, machine learning, and bioinformatics pipelines to analyze whole-genome sequencing data from tens of thousands of participants, enabling the detection of rare and common genetic variants at scale.
Are deCODE's research findings publicly available?
Yes, deCODE regularly publishes its discoveries in major peer-reviewed journals such as Nature Genetics, making findings accessible to the global scientific and medical community.
Who can access deCODE's genetics data and services?
deCODE primarily collaborates with pharmaceutical companies, academic research institutions, and operates internally within Amgen's drug discovery programs. It is not a consumer or self-service platform.
